Australia Becomes First Country to Schedule BPC-157 as Prescription-Only

Australia's Therapeutic Goods Administration (TGA) added the experimental peptide BPC-157 to Schedule 4 of the Poisons Standard, the category for prescription-only medicines, with the change taking effect on June 1, 2024. The decision, made through the TGA's scheduling process following advisory committee consultation, was described by regulatory and anti-doping bodies as the first time any country had specifically scheduled BPC-157 in its national medicines framework.

Schedule 4 status does not ban the substance outright; rather, it restricts lawful supply to a prescription written by a registered medical practitioner, with preparation typically handled through a compounding pharmacy. Importantly, BPC-157 is not an approved therapeutic good in Australia: no product containing it is registered on the Australian Register of Therapeutic Goods (ARTG), and it remains an unapproved, experimental substance.

In its scheduling rationale, the TGA delegate pointed to rising importation of the peptide, online marketing that made therapeutic claims, and the absence of completed human clinical trials establishing safety and efficacy. The published reasoning noted that the agency had received 48 referrals for importation of BPC-157 since July 1, 2022, and expressed concern about use occurring outside medical supervision in fitness, wellness and anti-ageing markets.

The scheduling decision fit within a broader TGA posture on peptides. The agency has issued guidance and safety communications reminding importers, compounders and suppliers of their obligations regarding unapproved peptide products, and has flagged public-health risks associated with products marketed for performance, recovery or cosmetic purposes without regulatory evaluation. In sport, BPC-157 is prohibited at all times under the World Anti-Doping Agency's S0 category for non-approved substances, according to Sport Integrity Australia.

Australia's approach contrasted with the regulatory path in the United States, where the FDA had restricted BPC-157 from use in pharmacy compounding in 2023 and, as of 2026, had scheduled an advisory-committee review of whether to reconsider that position. In both jurisdictions, BPC-157 remained an unapproved substance without an authorized therapeutic indication. This report describes regulatory status and does not offer medical or dosing advice.